Liposome mitigation of curcumin inhibition of cardiac potassium delayed-rectifier current

Journal of Receptor, Ligand and Channel Research

Volumn 5, Issue , 2012, Pages

  Helson, Lawrence ^a   Shopp, George ^b   Bouchard, Annie ^c   Majeed, Muhammad ^d  

^a SignPath Pharma   (United States)

^b IPS Therapeutique Inc ^*

^c IPS Therapeutique Inc   (Canada)

^d Sabinsa Inc   (United States)

Author keywords

hERG; Ion channel; Torsade de point

Indexed keywords

1 [2 (6 METHYL 2 PYRIDYL)ETHYL] 4 (4 METHYLSULFONYLAMINOBENZOYL)PIPERIDINE; CURCUMIN; DELAYED RECTIFIER POTASSIUM CHANNEL; LIPOSOME; POTASSIUM CHANNEL HERG; TERFENADINE;

ARTICLE; CELL STRAIN HEK293; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFECT; DRUG EXPOSURE; DRUG FORMULATION; GENETIC TRANSFECTION; HERG GENE; HUMAN; HUMAN CELL; INHIBITION KINETICS; PATCH CLAMP; POTASSIUM CURRENT;

EID: 84869795139     PISSN: None     EISSN: 1178699X     Source Type: Journal    
DOI: 10.2147/JRLCR.S37138     Document Type: Article

References (10)

1. Stansfeld PJ, Gedeck P, Gosling M, Cox B, Mitcheson JS, Sutclif MJ. Drug block of the hERG potassium channel: insight from modeling. Proteins. 2007;68(2):568-580.
2. Jervell A, Lang-Nielson F. Congenital deaf-mutism, functional heart disease with prolongation of the QT interval and sudden death. Am Heart J. 1957;54:59-68.
3. Zhou Z, Gong Q, January CT. Correction of defective protein trafficking of a mutant HERG potassium channel in human long QT syndrome: pharmacological and temperature effects. J Biol Chem. 1999;274: 31123-31126.
4. Anderson CL, Delisle BP, Anson BD, et al. Most LQT2mutations reduce Kv11.1 (hERG) current by a class 2 (trafficking deficient) mechanism. Circulation. 2006;113:365-373.
5. Moha ou Maati H, Ducroq J, Rivet J, Faivre JF, Le Grande M, Bois P. Curcumin blocks the recombinant human cardiac KCNQ1/KCNE1 channels (IKs) stably expressed in HEK 293cells. Congress de Physiologie de Pharmacologie et de Therapeutique; April 9-11, 2008; Clermont-Ferrand, France. Fund Clin Pharmacol. 2008;22(Suppl 1):1-102.
6. Yap YG, Camm AJ. Drug induced QT prolongation and torsades de pointes. Heart. 2003;89:1363-1372.
7. Okada T, Ogawa S, Sadanaga T, Mitamura H. Assessment of reverse use-dependent blocking actions of class III antiarrhythmic drugs by 24-hour Holter electrocardiography. J Am Coll Cardiol. 1996;27:84-89.
8. Maciel NR, Reis PG, Kato KC, et al. Reduced cardio-vascular alterations of tarter emetic administered in long-circulating liposomes in rats. Toxicol Lett. 2010;199(3):234-238.
9. Zachariae U, Giordanetto F, Leach AG. Side chain flexibilities in the human ether-a-go-go related potassium channel (hERG) together with matched-pair binding studies suggest a new binding mode for channel blockers. J Med Chem. 2009;52(14):4266-4276.
10. Mehta RT, Hopfer RL, Gunner LA, Juliano RL, Lopez-Berestein G. Formulation, toxicity, and antifungal activity in vitro of liposomal-encapsulated nystatin as therapeutic agent for systemic candidiasis. Antimicrob Agents Chemother. 1987;31(12):1897-1900.